Reata Pharmaceuticals, Inc. (NASDAQ:RETA) is set to announce second quarter earning results on Monday 10th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, RETA to report 2Q20 loss of $ 2.84 per share from revenue of $ 1.04 million.
For the full year, analysts anticipate top line of $ 4.30 million, while looking forward to loss of $ 9.28 per share bottom line.
Previous Quarter Performance
Reata Pharmaceuticals, Inc. came out with loss for the first quarter of $ 1.47 per share, from the revenue of $ 1.35 million. Wall street analysts are predicting, RETA to report 1Q20 loss of $ 1.98 per share from revenue of $ 2.04 million. The bottom line results beat street analysts by $ 0.51 or 25.76 percent, at the same time, top line results fell short of analysts by $ 0.69 million or 33.82 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Reata Pharmaceuticals, Inc.
Stock Performance
According to the previous trading day, closing price of RETA was $ 156.20, representing a 123.14 % increase from the 52 week low of $ 70.00 and a 39.45 % decrease over the 52 week high of $ 257.97.
The company has a market capital of $ 5.24 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”RETA” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Reata Pharmaceuticals, Inc. will be hosting a conference call at 8:30 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.reatapharma.com
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreichs ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc.
